Difference between revisions of "Meindl-Beinker NM, et al. BMC Cancer (2019) cited as Ref 636 in DOI: 10.1038/s41392-020-0110-5 (Q9899)"
Jump to navigation
Jump to search
(Created claim: title (P93): A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA), #quickstatements; #temporary_b...) |
(Created claim: Page(s) (P105): 231-, #quickstatements; #temporary_batch_1590074839150) |
||
Property / Page(s) | |||
+ | 231- | ||
Property / Page(s): 231- / rank | |||
+ | Normal rank |
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language | Label | Description | Also known as |
---|---|---|---|
English |
Meindl-Beinker NM, et al. BMC Cancer (2019) cited as Ref 636 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Meindl-Beinker NM
0 references
2019
0 references
BMC Cancer
0 references
19
0 references
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) (English)
0 references
231-
0 references